{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:38:47Z","timestamp":1790041127241,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.expneurol.2009.11.018","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T09:35:56Z","timestamp":1259919356000},"page":"329-334","source":"Crossref","is-referenced-by-count":70,"title":["The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: Clinical relevance"],"prefix":"10.1016","volume":"221","author":[{"given":"Patricia K.","family":"Sonsalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Yoong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Winnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2009.11.018_bib1","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1523\/JNEUROSCI.23-34-10982.2003","article-title":"Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively","volume":"23","author":"Alfinito","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2009.11.018_bib2","first-page":"1","article-title":"Protective effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone-related neurotoxicity","volume":"158","author":"Asanuma","year":"2007","journal-title":"Society for Neuroscience Program Nol"},{"key":"10.1016\/j.expneurol.2009.11.018_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.neures.2007.10.002","article-title":"Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation","volume":"60","author":"Asanuma","year":"2008","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.expneurol.2009.11.018_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2007.04.002","article-title":"Interactions between two enantiomers of losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model\u2014an isobolographic analysis","volume":"567","author":"Borowicz","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib6","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2009.11.018_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568026053386962","article-title":"Mechanisms of action of antiepileptic drugs","volume":"5","author":"Czapinski","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.expneurol.2009.11.018_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0022-3565(25)24767-X","article-title":"Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice","volume":"257","author":"Giovanni","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.11.018_bib9","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1073\/pnas.85.16.6172","article-title":"Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"85","author":"Heikkila","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2009.11.018_bib10","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.bmc.2005.12.057","article-title":"Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke","volume":"14","author":"Khalil","year":"2006","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.expneurol.2009.11.018_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","article-title":"Mechanisms of T-type calcium channel blockade by zonisamide","volume":"5","author":"Kito","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2009.11.018_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jep.2004.01.013","article-title":"Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones","volume":"91","author":"Kong","year":"2004","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","article-title":"Molecular targets for antiepileptic drug development","volume":"4","author":"Meldrum","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.expneurol.2009.11.018_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide","volume":"20","author":"Mimaki","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.expneurol.2009.11.018_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1528-1157.1997.tb01479.x","article-title":"Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats","volume":"38","author":"Minato","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2009.11.018_bib16","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1046\/j.1471-4159.2000.0741656.x","article-title":"Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures","volume":"74","author":"Moy","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2009.11.018_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.bjp.0704285","article-title":"Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis","volume":"134","author":"Murakami","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2009.11.018_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0006-8993(96)82386-9","article-title":"Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse","volume":"731","author":"Nagatomo","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2009.11.018_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0361-9230(00)00333-6","article-title":"Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice","volume":"53","author":"Nagatomo","year":"2000","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.expneurol.2009.11.018_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2009.11.018_bib22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2165\/00003495-199345050-00010","article-title":"Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy","volume":"45","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2009.11.018_bib23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1289\/ehp.9932","article-title":"Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain","volume":"115","author":"Prasad","year":"2007","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.expneurol.2009.11.018_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/bjp.2008.78","article-title":"The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B","volume":"154","author":"Quinn","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1471-4159.2008.05355.x","article-title":"Na(+)\/H(+) exchanger inhibition modifies dopamine neurotransmission during normal and metabolic stress conditions","volume":"106","author":"Rocha","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2009.11.018_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","article-title":"Monoamine oxidase: from genes to behavior","volume":"22","author":"Shih","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2009.11.018_bib27","first-page":"683","article-title":"Zonisamide: a new antiepileptic drug","volume":"55","author":"Sobieszek","year":"2003","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0022-3565(25)39183-4","article-title":"Characteristics of 1-methyl-4-(2\u2032-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse","volume":"242","author":"Sonsalla","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.11.018_bib29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1023\/A:1007622129369","article-title":"In vivo evaluation of hippocampal anti-oxidant ability of zonisamide in rats","volume":"25","author":"Tokumaru","year":"2000","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2009.11.018_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s11064-005-7586-9","article-title":"In vivo evaluation of the effect of zonisamide on the hippocampal redox state during kainic acid-induced seizure status in rats","volume":"30","author":"Ueda","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2009.11.018_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1254\/jphs.09019FP","article-title":"Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP","volume":"110","author":"Yabe","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2009.11.018_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00210-007-0135-0","article-title":"Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists","volume":"375","author":"Yang","year":"2007","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.11.018_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1471-4159.1987.tb05606.x","article-title":"Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"48","author":"Youngster","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2009.11.018_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1055\/s-2001-11500","article-title":"Inhibition of xanthine and monoamine oxidases by stilbenoids from Veratrum taliense","volume":"67","author":"Zhou","year":"2001","journal-title":"Planta Med."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488609004762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488609004762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:38:44Z","timestamp":1739464724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488609004762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0014488609004762"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2009.11.018","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}